Sector News

Job losses loom as Roche restructures for specialised drugs

November 13, 2015
Life sciences

Roche is restructuring its manufacturing network for small molecules to focus on specialised medicines produced in lower volumes.

As a result the Swiss company will exit four manufacturing sites in Clarecastle, Ireland; Leganes, Spain; Segrate, Italy; and Florence, United States. It will also invest 300 million Swiss francs (CHF) into a dedicated facility in Kaiseraugst, Switzerland to support “future technology requirements” for this new generation of specialised medicines.

“With these changes we are responding to the evolution of our small molecule portfolio towards specialised medicines produced in lower volumes,” says Daniel O’Day, chief operating officer of Roche’s pharmaceuticals division of Roche. “We are aware of the impact this decision has on our colleagues, and we will do our utmost to support them during this transition.”

In an effort to minimise job reductions, the company is looking into divestment opportunities for the closed facilities and will immediately begin discussions with employee representatives in the respective countries. It estimates that the closures will affect around 1,200 positions.

Transition will begin in 2016 and is planned to end by 2021.

It is expected that site exits will result in non-core restructuring costs of CHF 1.6 billion until 2021, of which up to CHF 600 million will be in cash. This also includes additional efficiency efforts undertaken in the manufacturing network and organisation. Roche says that estimated non-core costs in 2015 are up to CHF 800 million, with only a minor cash flow impact in 2015.

Source: Pharma Times

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach